群益证券给予恒瑞医药买进评级，主业稳步增长，BD收益增厚利润，25H1净利YOY+30%

Group 1 - The core viewpoint of the report is that Everbright Securities has given a "buy" rating for Heng Rui Medicine (600276.SH) based on several positive factors [2] - The main reasons for the rating include the growth driven by innovative revenue from the core business, and the expectation that BD transaction income will continue to enhance net profit in the second half of the year [2] - The report also highlights the A-share employee stock ownership plan and the A-share repurchase plan as supportive measures for the company's stock performance [2] Group 2 - The report includes profit forecasts and investment recommendations, indicating a positive outlook for the company's financial performance [2] - Potential risks mentioned include the progress of new drug development and sales not meeting expectations, as well as risks related to foreign exchange gains and losses [2]